PMID- 20232066
OWN - NLM
STAT- MEDLINE
DCOM- 20100709
LR  - 20131121
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 89
IP  - 8
DP  - 2010 Aug
TI  - Consensus guidelines for the optimal management of adverse events in newly 
      diagnosed, transplant-ineligible patients receiving melphalan and prednisone in 
      combination with thalidomide (MPT) for the treatment of multiple myeloma.
PG  - 803-11
LID - 10.1007/s00277-010-0925-1 [doi]
AB  - Thalidomide has received approval from the European Agency for the Evaluation of 
      Medicinal Products for the treatment of newly diagnosed multiple myeloma (MM) 
      patients older than 65 years or ineligible for transplant. The results of five 
      phase III trials assessing thalidomide in combination with melphalan and 
      prednisone (MPT) have demonstrated significantly improved response rates compared 
      with melphalan and prednisone (MP) alone. Additionally, two of these studies 
      showed that survival was extended by approximately 18 months in patients treated 
      with MPT compared with MP alone. Thalidomide, in combination with MP, is 
      associated with adverse events (AEs) including peripheral neuropathy and venous 
      thromboembolism. In order to optimize the efficacy of MPT, a good awareness of 
      these AEs is imperative. This manuscript outlines both evidence- and 
      consensus-based recommendations discussed by a panel of experts, to provide a 
      practical guide for physicians addressing the effective management of newly 
      diagnosed, transplant-ineligible MM patients receiving thalidomide therapy.
FAU - Palumbo, A
AU  - Palumbo A
AD  - University of Torino, Turin, Italy. appalumbo@yahoo.com
FAU - Davies, F
AU  - Davies F
FAU - Kropff, M
AU  - Kropff M
FAU - Blade, J
AU  - Blade J
FAU - Delforge, M
AU  - Delforge M
FAU - Leal da Costa, F
AU  - Leal da Costa F
FAU - Garcia Sanz, R
AU  - Garcia Sanz R
FAU - Schey, S
AU  - Schey S
FAU - Facon, T
AU  - Facon T
FAU - Morgan, G
AU  - Morgan G
FAU - Moreau, P
AU  - Moreau P
LA  - eng
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Practice Guideline
PT  - Research Support, Non-U.S. Gov't
DEP - 20100316
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - Q41OR9510P (Melphalan)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Aged
MH  - *Consensus
MH  - Europe
MH  - *Guidelines as Topic
MH  - Humans
MH  - *Melphalan/adverse effects/therapeutic use
MH  - Multiple Myeloma/diagnosis/*drug therapy
MH  - *Prednisone/adverse effects/therapeutic use
MH  - Risk Factors
MH  - Survival Rate
MH  - *Thalidomide/adverse effects/therapeutic use
MH  - Thromboembolism/etiology/prevention & control
RF  - 75
EDAT- 2010/03/17 06:00
MHDA- 2010/07/10 06:00
CRDT- 2010/03/17 06:00
PHST- 2009/12/15 00:00 [received]
PHST- 2010/02/08 00:00 [accepted]
PHST- 2010/03/17 06:00 [entrez]
PHST- 2010/03/17 06:00 [pubmed]
PHST- 2010/07/10 06:00 [medline]
AID - 10.1007/s00277-010-0925-1 [doi]
PST - ppublish
SO  - Ann Hematol. 2010 Aug;89(8):803-11. doi: 10.1007/s00277-010-0925-1. Epub 2010 Mar 
      16.